12:00 AM
 | 
Jan 28, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Oral rigosertib: Phase I start

In March, SymBio will begin an open-label, dose-escalation, Japanese Phase I trial to evaluate 280 and 560 mg oral rigosertib twice daily for 14 consecutive days of a 21-day cycle for about 6 cycles in up to 12 MDS patients who failed,...

Read the full 190 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >